GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Debt-to-Asset

HLS Therapeutics (TSX:HLS) Debt-to-Asset : 0.43 (As of Mar. 2024)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Debt-to-Asset?

HLS Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$6.94 Mil. HLS Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$108.25 Mil. HLS Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was C$267.68 Mil. HLS Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.43.


HLS Therapeutics Debt-to-Asset Historical Data

The historical data trend for HLS Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Debt-to-Asset Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.35 0.35 0.40 0.42

HLS Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.42 0.42 0.42 0.43

Competitive Comparison of HLS Therapeutics's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Debt-to-Asset falls into.



HLS Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

HLS Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.917 + 110.635) / 280.475
=0.42

HLS Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.94 + 108.247) / 267.676
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (TSX:HLS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


HLS Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (TSX:HLS) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.
Executives
Polar Asset Management Partners Inc. 10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines